Sodium stibogluconate (Pentostan) overdose in a patient with acquired immunodeficiency syndrome

Therapeutic Drug Monitoring

Volumn 20, Issue 6, 1998, Pages 714-716

  Reymond, Jean Marc ^a   Desmeules, Jules ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Overdose; Pentostan; Pharmokinetics; Stibogluconate

Indexed keywords

AMPHOTERICIN B; AMYLASE; CLARITHROMYCIN; CLOFAZIMINE; PENTAMIDINE; RIFABUTIN; STIBOGLUCONATE SODIUM; TRIACYLGLYCEROL LIPASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD CULTURE; CASE REPORT; CLINICAL FEATURE; DRUG ELIMINATION; DRUG OVERDOSE; ENZYME BLOOD LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PLASMA HALF LIFE; PRIORITY JOURNAL; VISCERAL LEISHMANIASIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AMYLASES; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; HALF-LIFE; HUMANS; LEISHMANIASIS, VISCERAL; LIPASE; MALE; MEDICATION ERRORS; SUCCIMER; TIME FACTORS; TOMOGRAPHY SCANNERS, X-RAY COMPUTED;

EID: 0031785954     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199812000-00023     Document Type: Article

References (14)

1. Miralles P, Moreno S, Pérez-Tascón M, et al. Fever of uncertain origin in patients infected with the human immunodeficiency virus. Clin Infect Dis 1995;20:872-5.
2. Berenguer J, Moreno S, Cercenado E, et al. Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV). Ann Intern Med 1989;111:129-32.
3. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentosotam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992;46:296-306.
4. Peters BS, Fish D, Golden R, et al. Visceral leishmaniasis in HIV infection and AIDS: Clinical features and response to therapy. Q J Med 1990;283:1101-11.
5. Thakur CP. Harmful effect of high stibogluconate treatment of kala-azar in India. Trans R Soc Trop Med Hyg 1986;80:672-3.
6. Gasser RA Jr, Magill AJ. Oster CN, et al. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994;18:83-90.
7. Laguna F, Soriano V, González-Lahoz JM. Misdiagnosis of pancreatitis in patients receiving treatment with pentavalent antimonial agents [letter]. Clin Infect Dis 1994;19:978-9.
8. Chulay JD, Fleckenstein L, Smith DH. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans R Soc Trop Med Hyg 1988;82:69-72.
9. Herwaldt BL, Kaye ET, Lepore TJ, et al. Sodium stibogluconate overdose during treatment of American cutaneous leishmaniasis. J Infect Dis 1993;17:56-8.
10. Whitney TM, Macho JR, Russell TR, et al. Appendicitis in acquired immunodeficiency syndrome. Am J Surg 1992;164:467-71.
11. De Gruyter MW. Analytical toxicology for clinical forensic and pharmaceutical chemists. In: Brandberger H, ed. 1997:332-3.
12. Rees PH, Keating MI, Kager PA, et al. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet 1980;2:226-9.
13. Mishra M, Biswas UK, Jha AM, et al. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 1994;344:1599-1600.
14. De Górgolas M, Castrillo JM, Fernández Guerrero ML. Visceral leishmaniasis in patients with AIDS: Report of three cases treated with pentavalent antimony and interferon-γ. Clin Infect Dis 1993; 17:56-8.